Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like GlaxoSmithKline's Pain in China is AstraZeneca's Gain November 8, 2017 Eli Lilly Seeks "Voluntary Exits" From 200 Researchers February 5, 2017 New Data Reveals This New York Biotech's Pipeline Could be a Game Changer June 15, 2017